Identifying biomarkers in lung cancer patients in Malaysia
Biomarker Discovery in Lung Cancer - Malaysia
This study is trying to find specific markers in the blood of lung cancer patients in Malaysia to help doctors better identify high-risk individuals and improve follow-up care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 30 Years and up |
| Sex | All |
| Sponsor | University of Malaya Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Kuala Lumpur) |
| Trial ID | NCT06504927 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify biomarkers and signatures that can differentiate between high-risk individuals and lung cancer patients. It focuses on discovering blood-based biomarkers that serve as adjunct tests to imaging diagnoses, thereby improving patient follow-up. The study hypothesizes that changes in cell-free DNA and RNA expression during disease progression can yield valuable biomarker signatures. Participants will provide blood samples and imaging results to facilitate this research.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 30 and above with COPD or pulmonary nodules who have no previous history of cancer.
Not a fit: Patients who have received cancer treatment or are currently pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and monitoring of lung cancer through blood-based biomarkers.
How similar studies have performed: Other studies have shown promise in using liquid biopsies for cancer detection, indicating that this approach has potential based on existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female subjects aged 30 and above. * No previous history of any cancers. * Able to provide X-ray and/or LDCT results. * Have either COPD or pulmonary nodules measuring less than 11mm, or deemed not for biopsy by attending physician * Willing to go back for a follow-up X-ray or LDCT scan in the next clinical follow up as per standard of care. * Willing to provide up to 30mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit). Exclusion Criteria: * Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment. * Subject is pregnant or lactating (self-declaration). * Subject is unwilling or unable to provide signed informed consent
Where this trial is running
Kuala Lumpur
- University of Malaya Medical Centre — Kuala Lumpur, Malaysia (Recruiting)
Study contacts
- Principal investigator: Mau Ern Poh — University of Malaya
- Study coordinator: Mau Ern Poh
- Email: ernestpoh@gmail.com
- Phone: +60379494422
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.